Ginkgo Bioworks Files SC 13D for Bolt Projects Holdings

TL;DR

Ginkgo Bioworks just filed a 13D on Bolt Projects Holdings. Big changes coming?

AI Summary

Ginkgo Bioworks Holdings, Inc. filed an SC 13D on August 20, 2024, regarding Bolt Projects Holdings, Inc. The filing indicates a change in beneficial ownership for Bolt Projects Holdings, Inc., formerly known as Golden Arrow Merger Corp. The filing was made by Ginkgo Bioworks, Inc., with Mark Dmytruk, CFO, listed as the authorized contact.

Why It Matters

This filing signals a potential shift in control or significant stake acquisition in Bolt Projects Holdings by Ginkgo Bioworks, which could impact the future strategic direction and valuation of Bolt Projects Holdings.

Risk Assessment

Risk Level: medium — SC 13D filings often precede significant corporate actions or changes in control, introducing uncertainty and potential volatility for the involved companies.

Key Players & Entities

• Ginkgo Bioworks Holdings, Inc. (company) — Filer of the SC 13D
• Bolt Projects Holdings, Inc. (company) — Subject company of the SC 13D
• Mark Dmytruk (person) — Chief Financial Officer of Ginkgo Bioworks, Inc., authorized to receive notices
• Golden Arrow Merger Corp. (company) — Former name of Bolt Projects Holdings, Inc.

FAQ

Key Financial Figures

• $0.0001 — relates to the common stock, par value $0.0001 per share (the Common Stock ) of Bolt P
• $30 million — ate original stated principal amount of $30 million. The acquisition of the Senior Secured
• $10 million — Secured Notes in a principal amount of $10 million for a convertible note in the original

Filing Documents

• d881346dsc13d.htm (SC 13D) — 68KB
• d881346dex991.htm (EX-99.1) — 4KB
• 0001193125-24-203635.txt ( ) — 75KB

herein

Item 5 herein. 13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 8.5% (2) 14. TYPE OF REPORTING PERSON (see instructions) CO (1) Consists of 2,679,319 shares of Common Stock of the Issuer held by Ginkgo Bioworks, a wholly owned subsidiary of Ginkgo. Shares of Common Stock of the Issuer held by Ginkgo Bioworks may be deemed beneficially owned by Ginkgo, its sole parent. (2) Based on 31,660,231 shares of Common Stock of the Issuer outstanding as of August 13, 2024, as reported on the Issuers Form 8-K filed August 19, 2024. CUSIP No. 09769B107 1. NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) Ginkgo Bioworks Holdings, Inc. 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions) (a)(b) 3. SEC USE ONLY 4. SOURCE OF FUNDS (see instructions) OO 5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) 6. CITIZENSHIP OR PLACE OF ORGANIZATION Delaware NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 7. SOLE VOTING POWER 0 8. SHARED VOTING POWER 2,679,319 (1) 9. SOLE DISPOSITIVE POWER 0 10. SHARED DISPOSITIVE POWER 2,679,319 (1) 11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 2,679,319 (1) 12. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions) See

herein

Item 5 herein. 13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 8.5% (2) 14. TYPE OF REPORTING PERSON (see instructions) CO (1) Consists of 2,679,319 shares of Common Stock of the Issuer held by Ginkgo Bioworks, a wholly owned subsidiary of Ginkgo. Shares of Common Stock of the Issuer held by Ginkgo Bioworks may be deemed beneficially owned by Ginkgo, its sole parent. (2) Based on 31,660,231 shares of Common Stock of the Issuer outstanding as of August 13, 2024, as reported on the Issuers Form 8-K filed August 19, 2024. Item1. Security and Issuer. This Schedule 13D (this Schedule 13D ) relates to the common stock, par value $0.0001 per share (the Common Stock ) of Bolt Projects Holdings, Inc., a Delaware corporation (the Issuer ) held by Ginkgo Bioworks, Inc. The principal executive offices of the Issuer are located at 2261 Market Street, Suite 5447, San Francisco, California 94114. Item2. Identity and Background. This Schedule 13D is being filed jointly by Ginkgo Bioworks, Inc., a Delaware corporation ( Ginkgo Bioworks ), and Ginkgo Bioworks Holdings, Inc. ( Ginkgo ), a Delaware corporation (together, the Reporting Persons and each, a Reporting Person ). The agreement between the Reporting Persons relating to the joint filing is attached hereto as Exhibit 99.1 . The address of the principal business office of the Reporting Persons is 27 Drydock Avenue, 8 th Floor, Boston, Massachusetts 02210. The principal business occupation of the Reporting Persons is the provision of cell engineering and biosecurity services. The name, business address, present principal occupation or employment and citizenship of each director and executive officer of Ginkgo and Ginkgo Bioworks are set forth on Schedule A hereto. During the last five years none of the Reporting Persons have, and to the best of the Reporting Persons knowledge, none of the persons listed on Schedule A hereto has: (i) been convicted in a criminal proceeding (excluding traffic viola

View Full Filing

View this SC 13D filing on SEC EDGAR